Arrowhead Pharmaceuticals (ARWR) said Monday that topline results of the clinical study of its investigational RNA interference therapeutic ARO-C3 showed an 89% mean reduction in complement component 3, supporting it as a potential therapy for various complement-mediated diseases.
The second part of the phase 1/2 clinical study also showed reductions of 85% in AH50 and 100% in Wieslab AP, which are both markers of alternative pathway complement activity, in patients with IgA nephropathy, the company said.
Arrowhead also reported that the therapy was generally well tolerated by the patients, with no serious or severe treatment adverse events.
The study was designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of adult healthy volunteers and adult patients with complement-mediated renal disease.
The company said it plans to present additional results at an upcoming medical meeting later this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.